Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 10/2016

Open Access 01-10-2016 | Article

Maternal overweight and obesity and risk of pre-eclampsia in women with type 1 diabetes or type 2 diabetes

Authors: Martina Persson, Sven Cnattingius, Anna-Karin Wikström, Stefan Johansson

Published in: Diabetologia | Issue 10/2016

Login to get access

Abstract

Aims/hypothesis

Women with type 1 or type 2 diabetes are at increased risk of pre-eclampsia. Overweight and obesity are associated with an increased risk of pre-eclampsia in women without diabetes. The aim of the study was to investigate the impact of maternal overweight and obesity on the risk of pre-eclampsia in women with type 1 diabetes or type 2 diabetes.

Methods

In a population-based cohort study including singleton births in Sweden, we estimated the risk of pre-eclampsia among women with type 1 diabetes (n = 7062) and type 2 diabetes (n = 886), and investigated whether maternal overweight (BMI 25–29.9 kg/m2) and obesity (BMI ≥30.0 kg/m2) modified the risk. Logistic regression analyses were used to estimate crude and adjusted ORs with 95% CIs, using women without diabetes as the reference group (n = 1,509,525).

Results

Compared with women without diabetes, the adjusted ORs for pre-eclampsia in women with type 1 and type 2 diabetes were 5.74 (95% CI 5.31, 6.20) and 2.11 (95% CI 1.65, 2.70), respectively. The corresponding risks of pre-eclampsia combined with preterm birth were even higher. Risks of pre-eclampsia increased with maternal overweight (BMI 25–29.9 kg/m2) and obesity (BMI ≥30.0 kg/m2), foremost in women without diabetes, to a lesser extent in women with type 1 diabetes but not in women with type 2 diabetes.

Conclusions/interpretation

Maternal overweight and obesity increased risks of pre-eclampsia in women with type 1 diabetes but not in women with type 2 diabetes. Even so, considering associations between maternal BMI and overall maternal and offspring risk, all women (with and without diabetes) should aim for a normal weight before pregnancy.
Literature
1.
Persson M, Norman M, Hanson U (2009) Obstetric and perinatal outcomes in type 1 diabetic pregnancies: a large, population-based study. Diabetes Care 32:2005–2009CrossRefPubMedPubMedCentral
2.
Murphy HR, Steel SA, Roland JM et al (2011) Obstetric and perinatal outcomes in pregnancies complicated by type 1 and type 2 diabetes: influences of glycaemic control, obesity and social disadvantage. Diabetic Medi: J Br Diabetic Assoc 28:1060–1067CrossRef
3.
4.
Spradley FT, Palei AC, Granger JP (2015) Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms. Am J Physiol Regul Integr Comp Physiol 309:R1326–R1343CrossRefPubMed
5.
Goldenberg RL, Culhane J, Iams JD, Romero R (2008) Epidemiology and causes of preterm birth. Lancet (London, England) 371:75–84CrossRef
6.
Xiong X, Buekens P, Pridjian G, Fraser WD (2007) Pregnancy-induced hypertension and perinatal mortality. J Reprod Med 52:402–406PubMed
7.
8.
Duckitt K, Harrington D (2005) Risk factors for pre-eclampsia at antental booking: systemic review of controlled studies. Br Med J (Clin Res Ed) 330:549–550CrossRef
9.
Hanson U, Persson B (1998) Epidemiology of pregnancy-induced hypertension and preeclampsia in type 1 (insulin-dependent) diabetic pregnancies in Sweden. Acta Obstet Gynecol Scand 77:620–624CrossRefPubMed
10.
Klemetti MM, Laivuori H, Tikkanen M, Nuutila M, Hiilesmaa V, Teramo K (2015) White’s classification and pregnancy outcome in women with type 1 diabetes: a population-based cohort study. Diabetologia 59:92–100CrossRef
11.
Gordin D, Forsblom C, Groop PH, Teramo K, Kaaja R (2014) Risk factors of hypertensive pregnancies in women with diabetes and the influence on their future life. Ann Med 46:498–502CrossRefPubMed
12.
Ogden CL, Carroll MD, Fryar CD, Flegal KM (2015) Prevalence of obesity among adults and youth: United States, 2011–2014. NCHS Data Brief 2015 Nov. 1–8
13.
Klemetti M, Nuutila M, Tikkanen M, Kari MA, Hiilesmaa V, Teramo K (2012) Trends in maternal BMI, glycaemic control and perinatal outcome among type 1 diabetic pregnant women in 1989–2008. Diabetologia 55:2327–2334CrossRefPubMed
14.
Owens LA, Egan AM, Carmody L, Dunne F (2016) Ten years of optimizing outcomes for women with type 1 and type 2 diabetes in pregnancy – the Atlantic DIP experience. J Clin Endocrinol Metab 101:1598–1605CrossRefPubMed
15.
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study Cooperative Research Group (2010) Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia. Am J Obstet Gynecol 202(255):e251–e257
16.
Sohlberg S, Stephansson O, Cnattingius S, Wikstrom AK (2012) Maternal body mass index, height, and risks of preeclampsia. Am J Hypertens 25:120–125CrossRefPubMed
17.
Persson M, Pasupathy D, Hanson U, Westgren M, Norman M (2012) Pre-pregnancy body mass index and the risk of adverse outcome in type 1 diabetic pregnancies: a population-based cohort study. BMJ Open 2:e000601CrossRefPubMedPubMedCentral
18.
National Board of Health and Welfare (Socialstyrelsen) (2003) NBoHaW Swedish Medical Birth Register. A summary of content and quality. 2003-112-3. Available from www.​socialstyrelsens​e/​publikationer 2003/2003-112-3, accessed 15 June 2016
19.
Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A (2009) The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 24:659–667CrossRefPubMedPubMedCentral
20.
Ludvigsson JF, Almqvist C, Bonamy AE et al (2016) Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 31:125–136CrossRefPubMed
21.
Statistics Sweden (2015) Utvärdering av Utbildningsregistret [Evaluation of the Swedish Register of Education]. Accessed 21 May 2015 [in Swedish]
22.
23.
Sibai BM (2003) Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 102:181–192PubMed
24.
Ros HS, Cnattingius S, Lipworth L (1998) Comparison of risk factors for preeclampsia and gestational hypertension in a population-based cohort study. Am J Epidemiol 147:1062–1070CrossRefPubMed
25.
Klemmensen AK, Olsen SF, Osterdal ML, Tabor A (2007) Validity of preeclampsia-related diagnoses recorded in a national hospital registry and in a postpartum interview of the women. Am J Epidemiol 166:117–124CrossRefPubMed
26.
Fadl HEOI, Hanson US (2012) Outcomes of gestational diabetes in Sweden depending on country of birth. Acta Obstet Gynecol Scand 91:1326–1330CrossRefPubMed
27.
Perni UC, Wikström A, Cnattingius S, Villamr E (2012) Interpregnancy change in smoking habits and risk of preeclampsia: a population-based study. Am J Hypertens 25:372–378CrossRefPubMed
28.
Carnethon MR, De Chavez PJ, Biggs ML et al (2012) Association of weight status with mortality in adults with incident diabetes. JAMA 308:581–590PubMedPubMedCentral
29.
Cundy T, Slee F, Gamble G, Neale L (2002) Hypertensive disorders of pregnancy in women with Type 1 and Type 2 diabetes. Diabet Med: J Br Diabet Assoc 19:482–489CrossRef
30.
Balsells M, Garcia-Patterson A, Gich I, Corcoy R (2009) Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis. J Clin Endocrinol Metab 94:4284–4291CrossRefPubMed
31.
Starikov R, Inman K, Chen K et al (2014) Comparison of placental findings in type 1 and type 2 diabetic pregnancies. Placenta 35:1001–1006CrossRefPubMed
32.
Damm JA, Asbjornsdottir B, Callesen NF et al (2013) Diabetic nephropathy and microalbuminuria in pregnant women with type 1 and type 2 diabetes: prevalence, antihypertensive strategy, and pregnancy outcome. Diabetes Care 36:3489–3494CrossRefPubMedPubMedCentral
33.
34.
Klemetti MM, Laivuori H, Tikkanen M, Nuutila M, Hiilesmaa V, Teramo K (2015) Obstetric and perinatal outcome in type 1 diabetes patients with diabetic nephropathy during 1988–2011. Diabetologia 58:678–686CrossRefPubMed
35.
Yogev Y, Chen R, Ben-Haroush A, Hod M, Bar J (2010) Maternal overweight and pregnancy outcome in women with Type-1 diabetes mellitus and different degrees of nephropathy. J Matern Fetal Neonatal Med: Off J Eur Assoc Perinat Med Fed Asia Oceania Perinat Soc Int Soc Perinat Obstet 23:999–1003CrossRef
36.
Jensen DM, Damm P, Ovesen P et al (2010) Microalbuminuria, preeclampsia, and preterm delivery in pregnant women with type 1 diabetes: results from a nationwide Danish study. Diabetes Care 33:90–94CrossRefPubMed
37.
Hiilesmaa V, Suhonen L, Teramo K (2000) Glycaemic control is associated with pre-eclampsia but not with pregnancy-induced hypertension in women with type I diabetes mellitus. Diabetologia 43:1534–1539CrossRefPubMed
38.
Ramsay JE, Ferrell WR, Crawford L, Wallace AM, Greer IA, Sattar N (2002) Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J Clin Endocrinol Metab 87:4231–4237CrossRefPubMed
39.
Jarvie E, Hauguel-de-Mouzon S, Nelson SM, Sattar N, Catalano PM, Freeman DJ (2010) Lipotoxicity in obese pregnancy and its potential role in adverse pregnancy outcome and obesity in the offspring. Clin Sci (Lond) 119:123–129CrossRef
40.
Harmon AC, Cornelius DC, Amaral LM et al (2016) The role of inflammtion in the pathology of preeclampsia. Clin Sci 130:409–419CrossRefPubMed
41.
42.
Sewell MF, Huston-Presley L, Amini SB, Catalano PM (2007) Body mass index: a true indicator of body fat in obese gravidas. J Reprod Med 52:907–911PubMed
Metadata
Title
Maternal overweight and obesity and risk of pre-eclampsia in women with type 1 diabetes or type 2 diabetes
Authors
Martina Persson
Sven Cnattingius
Anna-Karin Wikström
Stefan Johansson
Publication date
01-10-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 10/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-4035-z

Other articles of this Issue 10/2016

Diabetologia 10/2016 Go to the issue

Short Communication

Metabolic flexibility and oxidative capacity independently associate with insulin sensitivity in individuals with newly diagnosed type 2 diabetes

Article

Placental endoplasmic reticulum stress in gestational diabetes: the potential for therapeutic intervention with chemical chaperones and antioxidants

Review

The quest to make fully functional human pancreatic beta cells from embryonic stem cells: climbing a mountain in the clouds

Review

Effects of exercise training on intrahepatic lipid content in humans

Article

The hepatic FOXQ1 transcription factor regulates glucose metabolism in mice

Article

Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits